{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:57:06Z","timestamp":1792652226142,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clnu.2026.106620","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:42:04Z","timestamp":1772610124000},"page":"106620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study"],"prefix":"10.1016","volume":"60","author":[{"given":"Angela T.H.","family":"Kwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moiz","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2026.106620_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.clnu.2026.106620_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12933-025-02608-9","article-title":"Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges","volume":"24","author":"Westermeier","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clnu.2026.106620_bib3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jpsychires.2023.05.041","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: a systematic review","volume":"164","author":"Cooper","year":"2023","journal-title":"J Psychiatr Res"},{"issue":"13","key":"10.1016\/j.clnu.2026.106620_bib4","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early parkinson\u2019s disease","volume":"390","author":"Meissner Wassilios","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnu.2026.106620_bib5","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.eclinm.2024.102429","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial","volume":"68","author":"L\u00fcthi","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.clnu.2026.106620_bib6","volume":"30","author":"McIntyre","year":"2025","journal-title":"CNS Spectr"},{"issue":"3","key":"10.1016\/j.clnu.2026.106620_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","volume":"13","author":"Ma","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.clnu.2026.106620_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.clnu.2026.106620_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.clnu.2026.106620_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.14740\/jocmr4987","article-title":"Oral semaglutide induces loss of body fat mass without affecting muscle mass in patients with type 2 diabetes","volume":"15","author":"Uchiyama","year":"2023","journal-title":"J Clin Med Res"},{"issue":"4","key":"10.1016\/j.clnu.2026.106620_bib11","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/jcsm.12434","article-title":"Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy","volume":"10","author":"Hong","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnu.2026.106620_bib12","doi-asserted-by":"crossref","first-page":"1240263","DOI":"10.3389\/fendo.2023.1240263","article-title":"Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study","volume":"14","author":"Volpe","year":"2023","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.clnu.2026.106620_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jama.2024.6586","article-title":"Is weight loss-induced muscle mass loss clinically relevant?","volume":"332","author":"Conte","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.clnu.2026.106620_bib14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2213-8587(24)00272-9","article-title":"Muscle matters: the effects of medically induced weight loss on skeletal muscle","volume":"12","author":"Prado","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"S4","key":"10.1016\/j.clnu.2026.106620_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clnu.2026.106620_bib16","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaf335","article-title":"Incretin receptor agonism, fat-free mass, and cardiorespiratory fitness: a narrative review","author":"Liu","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"156113","key":"10.1016\/j.clnu.2026.106620_bib17","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.clnu.2026.106620_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13916","article-title":"How do glucagon-like Peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: a systematic review and meta-analysis","volume":"26","author":"Anyiam","year":"2025","journal-title":"Obes Rev"},{"issue":"5","key":"10.1016\/j.clnu.2026.106620_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101681","article-title":"GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies","volume":"51","author":"Scheen","year":"2025","journal-title":"Diabetes Metab"},{"issue":"4","key":"10.1016\/j.clnu.2026.106620_bib20","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00330-019-06573-2","article-title":"Imaging of sarcopenia: old evidence and new insights","volume":"30","author":"Albano","year":"2020","journal-title":"Eur Radiol"},{"issue":"8","key":"10.1016\/j.clnu.2026.106620_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ejrad.2016.04.009","article-title":"Imaging of sarcopenia","volume":"85","author":"Sergi","year":"2016","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1016\/j.clnu.2026.106620_bib22","doi-asserted-by":"crossref","first-page":"11765","DOI":"10.1038\/s41598-020-68797-3","article-title":"Body composition analysis using CT and MRI: intra-individual intermodal comparison of muscle mass and myosteatosis","volume":"10","author":"Faron","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clnu.2026.106620_bib23","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41598-023-29827-y","article-title":"Total and regional appendicular skeletal muscle mass prediction from dual-energy X-ray absorptiometry body composition models","volume":"13","author":"McCarthy","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.clnu.2026.106620_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/JCMA.0000000000000807","article-title":"Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy","volume":"86","author":"Fan","year":"2023","journal-title":"J Chin Med Assoc"},{"issue":"3","key":"10.1016\/j.clnu.2026.106620_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.108975","article-title":"Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway","volume":"39","author":"Xu","year":"2025","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.clnu.2026.106620_bib26","doi-asserted-by":"crossref","first-page":"154044","DOI":"10.1016\/j.metabol.2019.154044","article-title":"Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents","volume":"103","author":"Gurjar","year":"2020","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.clnu.2026.106620_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/nu17010178","article-title":"Sarcopenia in MASLD-eat to beat steatosis, move to prove strength","volume":"17","author":"Cri\u015fan","year":"2025","journal-title":"Nutrients"},{"issue":"102043","key":"10.1016\/j.clnu.2026.106620_bib28","doi-asserted-by":"crossref","first-page":"102043","DOI":"10.1016\/j.mex.2023.102043","article-title":"Effects of physical exercise in sarcopenia on patients undergoing bariatric surgery: a protocol for a randomized clinical trial","volume":"10","author":"Santos","year":"2023","journal-title":"MethodsX"},{"issue":"3","key":"10.1016\/j.clnu.2026.106620_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13839","article-title":"Sarcopenia, muscle mass and protein intake in adults older than 65 years after earlier bariatric surgery","volume":"16","author":"Eksteen","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.clnu.2026.106620_bib30","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1038\/s41598-025-89806-3","article-title":"The impact of bariatric surgery and exercise on systemic immune inflammation index in patients with sarcopenia obesity","volume":"15","author":"Mendes","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2026.106620_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s11695-025-08015-z","article-title":"Predictors of low muscle strength and reduction in fat-free mass in multi-ethnic Asian populations undergoing bariatric-metabolic surgery","author":"Low","year":"2025","journal-title":"Obes Surg"},{"issue":"156057","key":"10.1016\/j.clnu.2026.106620_bib32","article-title":"The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation","volume":"161","author":"Stefanakis","year":"2024","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.clnu.2026.106620_bib33","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1038\/s41467-025-59485-9","article-title":"GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates","volume":"16","author":"Mastaitis","year":"2025","journal-title":"Nat Commun"},{"issue":"101880","key":"10.1016\/j.clnu.2026.106620_bib34","doi-asserted-by":"crossref","first-page":"101880","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol Metab"},{"key":"10.1016\/j.clnu.2026.106620_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s11154-025-09967-4","article-title":"New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?","author":"Ryan","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"10.1016\/j.clnu.2026.106620_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40520-024-02825-4","article-title":"Effect of Bimagrumab on body composition: a systematic review and meta-analysis","volume":"36","author":"Kanbay","year":"2024","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.clnu.2026.106620_bib37","doi-asserted-by":"crossref","first-page":"101200","DOI":"10.1016\/j.arr.2020.101200","article-title":"Sarcopenia - molecular mechanisms and open questions","volume":"65","author":"Wiedmer","year":"2021","journal-title":"Ageing Res Rev"},{"issue":"4","key":"10.1016\/j.clnu.2026.106620_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1573399810666140918121022","article-title":"Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II","volume":"10","author":"Cetrone","year":"2014","journal-title":"Curr Diabetes Rev"},{"issue":"7","key":"10.1016\/j.clnu.2026.106620_bib39","doi-asserted-by":"crossref","first-page":"166770","DOI":"10.1016\/j.bbadis.2023.166770","article-title":"Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice","volume":"1869","author":"Iwai","year":"2023","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.clnu.2026.106620_bib40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"issue":"7","key":"10.1016\/j.clnu.2026.106620_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.20724","article-title":"Patient out-of-pocket costs for type 2 diabetes medications when aging into medicare","volume":"7","author":"Barthold","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clnu.2026.106620_bib42","doi-asserted-by":"crossref","first-page":"1394506","DOI":"10.3389\/fendo.2024.1394506","article-title":"Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice","volume":"15","author":"Pantanetti","year":"2024","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.clnu.2026.106620_bib43","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","article-title":"A systematic review of the effect of semaglutide on lean mass: insights from clinical trials","volume":"25","author":"Bikou","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clnu.2026.106620_bib44","article-title":"Effects of semaglutide on muscle structure and function in the SLIM LIVER Study","author":"Ditzenberger","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.clnu.2026.106620_bib45","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209151","article-title":"Safety and efficacy of apitegromab in patients with spinal muscular atrophy types 2 and 3: The phase 2 TOPAZ study","volume":"102","author":"Crawford","year":"2024","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.clnu.2026.106620_bib46","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/jcsm.13445","article-title":"Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: results from a randomized clinical trial","volume":"15","author":"Pandey","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnu.2026.106620_bib47","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.2147\/DDDT.S381546","article-title":"An effective glucagon-like Peptide-1 receptor agonists, semaglutide, improves sarcopenic obesity in Obese mice by modulating skeletal muscle metabolism","volume":"16","author":"Ren","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clnu.2026.106620_bib48","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/DMSO.S425642","article-title":"GLP-1RA Liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway","volume":"16","author":"Xiang","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"23","key":"10.1016\/j.clnu.2026.106620_bib49","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038444","article-title":"Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: a prospective cohort study","volume":"103","author":"Kakegawa","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.clnu.2026.106620_bib50","series-title":"FDA Adverse Event Reporting System (FAERS) public dashboard","year":"2023"},{"issue":"5","key":"10.1016\/j.clnu.2026.106620_bib51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.clnu.2026.106620_bib52","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.clnu.2026.106620_bib53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/dom.12389","article-title":"Fat-free mass loss generated with weight loss in overweight and obese adults: what may we expect?","volume":"17","author":"Dixon","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.clnu.2026.106620_bib54","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1017\/S0007114507691946","article-title":"Body fat and fat-free mass inter-relationships: forbes's theory revisited","volume":"97","author":"Hall","year":"2007","journal-title":"Br J Nutr"},{"issue":"8","key":"10.1016\/j.clnu.2026.106620_bib55","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/pds.5624","article-title":"Sensitivity and specificity in signal detection with the reporting odds ratio and the information component","volume":"32","author":"Trillenberg","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.clnu.2026.106620_bib56","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures","volume":"15","author":"Ang","year":"2016","journal-title":"Expert Opin Drug Saf"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561426000476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561426000476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T14:17:16Z","timestamp":1776521836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561426000476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":56,"alternative-id":["S0261561426000476"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2026.106620","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2026.106620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106620"}}